218 related articles for article (PubMed ID: 28408181)
41. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
[TBL] [Abstract][Full Text] [Related]
42. Neonatal exposure to antigen induces a defective CD40 ligand expression that undermines both IL-12 production by APC and IL-2 receptor up-regulation on splenic T cells and perpetuates IFN-gamma-dependent T cell anergy.
Min B; Legge KL; Bell JJ; Gregg RK; Li L; Caprio JC; Zaghouani H
J Immunol; 2001 May; 166(9):5594-603. PubMed ID: 11313399
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide.
Karpus WJ; Kennedy KJ; Smith WS; Miller SD
J Neurosci Res; 1996 Aug; 45(4):410-23. PubMed ID: 8872901
[TBL] [Abstract][Full Text] [Related]
44. Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice.
Srivastava A; Arlian BM; Pang L; Kishimoto TK; Paulson JC
ACS Chem Biol; 2021 Oct; 16(10):1985-1993. PubMed ID: 34037371
[TBL] [Abstract][Full Text] [Related]
45. CD40 stimulation in vivo does not inhibit CD4+ T cell tolerance to soluble antigens.
Sun J; Van Houten N
Immunol Lett; 2002 Nov; 84(2):125-32. PubMed ID: 12270549
[TBL] [Abstract][Full Text] [Related]
46. Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization.
Mittal A; Raber AS; Schaefer UF; Weissmann S; Ebensen T; Schulze K; Guzmán CA; Lehr CM; Hansen S
Vaccine; 2013 Jul; 31(34):3442-51. PubMed ID: 23290836
[TBL] [Abstract][Full Text] [Related]
47. T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis.
Cross AH; Lyons JA; San M; Keeling RM; Ku G; Racke MK
Eur J Immunol; 1999 Oct; 29(10):3140-7. PubMed ID: 10540325
[TBL] [Abstract][Full Text] [Related]
48. Degenerate antigen recognition by CD4+ effector T cells in experimental autoimmune encephalomyelitis.
McRae BL; Karandikar NJ; Miller SD
J Neuroimmunol; 1997 May; 75(1-2):156-62. PubMed ID: 9143249
[TBL] [Abstract][Full Text] [Related]
49. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.
Getts DR; Martin AJ; McCarthy DP; Terry RL; Hunter ZN; Yap WT; Getts MT; Pleiss M; Luo X; King NJ; Shea LD; Miller SD
Nat Biotechnol; 2012 Dec; 30(12):1217-24. PubMed ID: 23159881
[TBL] [Abstract][Full Text] [Related]
50. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: a comparison between oral and peripheral tolerance.
Kennedy KJ; Smith WS; Miller SD; Karpus WJ
J Immunol; 1997 Jul; 159(2):1036-44. PubMed ID: 9218627
[TBL] [Abstract][Full Text] [Related]
51. Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis.
Kiptoo P; Büyüktimkin B; Badawi AH; Stewart J; Ridwan R; Siahaan TJ
Clin Exp Immunol; 2013 Apr; 172(1):23-36. PubMed ID: 23480182
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion.
Kim TS; Chung SW; Kim SH; Kang SN; Kang BY
Int J Cancer; 2000 Aug; 87(3):427-33. PubMed ID: 10897050
[TBL] [Abstract][Full Text] [Related]
53. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
Zheng H; Zhang H; Liu F; Qi Y; Jiang H
Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
[TBL] [Abstract][Full Text] [Related]
54. Expansion by self antigen is necessary for the induction of experimental autoimmune encephalomyelitis by T cells primed with a cross-reactive environmental antigen.
Carrizosa AM; Nicholson LB; Farzan M; Southwood S; Sette A; Sobel RA; Kuchroo VK
J Immunol; 1998 Oct; 161(7):3307-14. PubMed ID: 9759846
[TBL] [Abstract][Full Text] [Related]
55. Oral Administration of Lactococcus lactis Expressing Synthetic Genes of Myelin Antigens in Decreasing Experimental Autoimmune Encephalomyelitis in Rats.
Kasarello K; Kwiatkowska-Patzer B; Lipkowski AW; Bardowski JK; Szczepankowska AK
Med Sci Monit; 2015 May; 21():1587-97. PubMed ID: 26026273
[TBL] [Abstract][Full Text] [Related]
56. Controlled delivery of a metabolic modulator promotes regulatory T cells and restrains autoimmunity.
Gammon JM; Tostanoski LH; Adapa AR; Chiu YC; Jewell CM
J Control Release; 2015 Jul; 210():169-78. PubMed ID: 26002150
[TBL] [Abstract][Full Text] [Related]
57. Antigen-oriented T cell migration contributes to myelin peptide induced-EAE and immune tolerance.
Zheng P; Fu H; Wei G; Wei Z; Zhang J; Ma X; Rui D; Meng X; Ming L
Clin Immunol; 2016 Aug; 169():36-46. PubMed ID: 27327113
[TBL] [Abstract][Full Text] [Related]
58. Induction of antigen-specific immune tolerance using biodegradable nanoparticles containing antigen and dexamethasone.
Kim SH; Moon JH; Jeong SU; Jung HH; Park CS; Hwang BY; Lee CK
Int J Nanomedicine; 2019; 14():5229-5242. PubMed ID: 31371958
[TBL] [Abstract][Full Text] [Related]
59. APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR™) to Induce Antigen-Specific T Regulatory Type 1 Cells.
Pellerin L; Chen P; Gregori S; Hernandez-Hoyos G; Bacchetta R; Roncarolo MG
Front Immunol; 2018; 9():881. PubMed ID: 29887861
[TBL] [Abstract][Full Text] [Related]
60. Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands.
Murtaza A; Kuchroo VK; Freeman GJ
Int Immunol; 1999 Mar; 11(3):407-16. PubMed ID: 10221652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
